This content is not available in your region

GSK to buy Sierra Oncology for $1.9 billion

GSK to buy Sierra Oncology for $1.9 billion
GSK to buy Sierra Oncology for $1.9 billion   -   Copyright  Thomson Reuters 2022
By Reuters

– Britain’s GlaxoSmithKline has agreed to buy California-based biopharmaceutical company Sierra Oncology in a deal valued at $1.9 billion, the companies said on Wednesday.

Shareholders in Sierra, which focuses on targeted therapies for the treatment of rare forms of cancer, will receive $55 per share of common stock in cash, GSK said.